Physician profile
Taha Khalid
NPI 1730793738
$818.87
in general payments reported to CMS, 2019-2025
13 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $445 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $320.98 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $76.72 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $64.24 | 2023-2024 | |
| Pfizer INC. | $64.22 | 2024-2025 | |
| Cvrx, INC. | $52.37 | 2024 | Barostim Neo System |
| Silk Road Medical, INC. | $45.13 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Kestra Medical Technology Services, INC. | $35.24 | 2024 | Assure Wcd |
| Smith+Nephew, INC. | $33.45 | 2025 | Collagenase Santyl |
| Boston Scientific Corporation | $32.42 | 2025 | Watchman Access System |
| Abbvie INC. | $27.23 | 2023 | |
| Abbott Laboratories | $24.29 | 2024 | Cardiomems |
| Astrazeneca Pharmaceuticals LP | $21.47 | 2023 | Breztri |
| Janssen Scientific Affairs, LLC | $21.11 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taha Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.